AstraZeneca likely to run new global trial on Covid-19 vaccine, says CEO

AstraZeneca likely to run new global trial on Covid-19 vaccine, says CEO
AstraZeneca likely to run new global trial on Covid-19 vaccine, says CEO

Thank you for reading the news about AstraZeneca likely to run new global trial on Covid-19 vaccine, says CEO and now with the details

Aden - Yasmine El Tohamy - AstraZeneca is facing tricky questions about its success rate that could hinder its chances of getting approval.

AstraZeneca is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine, its chief executive Pascal Soriot was quoted as saying on Thursday after questions over the results from its late-stage study.

Instead of adding the trial arm to an ongoing US process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca's studies, Soriot was quoted as saying in a Bloomberg News report.

Also read: Coronavirus: Doubts over AstraZeneca's vaccine data risk delaying approval

"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Soriot was quoted as saying.

Soriot said it would probably be another "international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients".

The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy US and EU regulatory approval.

Several scientists have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90 per cent effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

Soriot said he did not expect the additional trial to delay UK and European regulatory approvals.

Clearance from the US Food and Drug Administration (FDA) may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, especially given the questions over the results, he said.

Authorisation in some countries is still expected before the end of the year, he added.

AstraZeneca research chief Mene Pangalos told Reuters on Monday that researchers had stumbled upon the half-dose regime by accident, saying a sub-group of the trial was given a smaller initial dose by mistake.

Earlier he had said that the firm would start discussions with the FDA to change the design of its experimental Covid-19 vaccine trial to add the more-effective dosage regime.

These were the details of the news AstraZeneca likely to run new global trial on Covid-19 vaccine, says CEO for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Khaleej Times and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

NEXT India's foreign ministry launches app to connect to citizens abroad